Qvin
Qvin provides the Q-Pad, an FDA-cleared diagnostic menstrual pad that passively collects dried menstrual blood samples for at-home, needle-free testing. The samples are mailed to a CLIA-certified lab for analysis of biomarkers like HbA1c and reproductive hormones, with validated correlations to venous blood (r 0.9). The company operates a vertically integrated platform covering collection, logistics, lab software, and biobanking.
- Medical Devices
- Healthcare Technology
- Biotechnology
- Hardware
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Traditional diagnostic testing for women's health conditions relies on invasive procedures such as blood draws, biopsies, and speculum-driven exams, which create barriers to access and deter regular monitoring. Menstrual blood, a biologically rich fluid containing endometrial cells, immune components, hormones, and protein biomarkers, remains an underutilized resource for systemic and gynecological health assessment.
Solution
Qvin provides the Q-Pad, a patented, FDA-cleared diagnostic menstrual pad that passively collects dried menstrual blood samples through an embedded Dried Menstrual Sample strip during normal menstruation. Users wear the pad as they would any menstrual product, then mail the sample to a CLIA-certified lab for analysis. Research validates that menstrual blood collected via the Q-Pad reliably mirrors venous blood biomarker profiles, with strong correlations for HbA1c (r = 0.96) and hormones such as TSH and AMH (r > 0.9). The company operates a vertically integrated platform controlling every step from order and manufacturing through collection, lab analysis, and biobanking, built around ISO 13485 quality standards. This approach enables needle-free, at-home testing that expands access to diagnostic insights and supports early detection of metabolic, hormonal, and reproductive conditions.
Target Audience
Primary customers are people who menstruate seeking non-invasive health monitoring, as well as diagnostic platforms, healthcare organizations, pharma/biotech companies running clinical trials, and country-level agencies interested in scalable women's health screening solutions.
Features
- FDA-cleared diagnostic menstrual pad (510(k) K231465) with embedded Dried Menstrual Sample strip for passive, at-home sample collection
- Needle-free and non-invasive alternative to blood draws, endometrial biopsies, and speculum-based exams
- Clinically validated biomarker correlations with venous blood for HbA1c, TSH, and AMH (r > 0.9)
- CLIA-certified laboratory analysis pipeline with full sample traceability from collection to biobank
- Vertically integrated platform covering order APIs, FDA-registered manufacturing, shipping logistics, lab software, and biobanking under ISO 13485
- CE marked in Europe and UKCA marked in the UK, with public regulatory records
- Research-backed utility for monitoring diabetes, hormonal disorders, HPV screening, and endometrial conditions